Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6251957 | 0.91 | MAPK14 (0.56) | AURKARPS6KB1MAPK14MAPK13KIT | |
| SCHEMBL7855408 | 0.85 | MAPK14 (0.64) | MAPK14KITDDR1 | |
| SCHEMBL3938171 | 0.84 | PPARG (0.61) | PPARGMAPK14MAPK13L3MBTL1LMNA | |
| SCHEMBL6968243 | 0.83 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL3932976 | 0.81 | MAPK14 (0.60) | PPARGMAPK14MAPK13L3MBTL1LMNA | |
| SCHEMBL6980722 | 0.81 | MAPK14 (0.65) | MAPK14 | |
| SCHEMBL3938272 | 0.80 | PPARG (0.59) | PPARGMAPK14MAPK13LMNARAB9A | |
| SCHEMBL5897072 | 0.80 | MAPK14 (0.64) | PPARGMAPK14MAPK13 | |
| SCHEMBL6253060 | 0.79 | MAPK13 (0.61) | PPARGMAPK14MAPK13LMNARAB9A | |
| SCHEMBL6254089 | 0.79 | MAPK13 (0.61) | PPARGMAPK14MAPK13LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163212-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-31 | — | — | EP | disclosed |
| US-6794380-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; ANTIALLERGENS | ASTRAZENECA AB (SE) | 2004-09-21 | — | — | US | disclosed |
| US-20030186966-A1 | Amide derivatives | ASTRAZENECA AB | 2003-10-02 | — | — | US | disclosed |
| US-6548514-B1 | Inhibitors of p38 kinase/cytokine suppressive binding protein (CSBP)/reactivating kinase (RK); 1-((pyridyl)aminocarbonyl)-3-((hetero)arylaminocarbonyl)benzene derivatives; treating cytokine related diseases and disorders | ASTRAZENECA AB (SE) | 2003-04-15 | — | — | US | disclosed |
| EP-1163212-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186966-A1 | Amide derivatives | IL6, IL6ST, IFNG | PPARG 822/4885BTK 1602/4885AURKA 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.